Evaporative Dry Eye Relief With MIEBO® (perfluorohexyloctane ophthalmic solution)

What this episode covers

Dry eye disease (DED) is a pervasive condition impacting millions globally, and recent data suggests around 86% of dry eye patients exhibit meibomian gland dysfunction (MGD) and resulting excessive tear evaporation as a core cause. As patient needs and lifestyles evolve, it’s clear that OTC artificial tears alone may not address the issues underlying evaporative dry eye. In this article, we will explore how specialists like Dr. Mila Ioussifova are helping improve dry eye management by prioritizing patient-centered approaches, deploying advanced diagnostics, and prescribing MIEBO for rapid, sustained relief.* Understanding the Complexity of DED Dry eye symptoms vary in severity but typically include fluctuating vision, irritation, and burning. Common causes of dry eye include environmental factors, increased screen time, systemic health issues, and certain medications. Evaporative DED develops when the lipid layer of the tear film is compromised, leading to excessive tear evaporation and an unstable tear film. This desiccating stress then triggers a vicious cycle of inflammation and tissue damage, which exacerbates symptoms and the disease if left untreated. Given the high prevalence of evaporative dry eye, professionals should routinely check for MGD in every patient. A Patient-Centered Approach to Evaporative DED Diagnosis Dr. Ioussifova’s practice exemplifies an advanced approach to evaporative DED management. Through specialized patient consultations, she establishes a rapport that enables her team to provide tailored care. Initial screening begins at the patient’s first call to the office, where trained staff ask about daily symptoms and screen for potential dry eye conditions. This structured intake ensures that each patient’s visit is customized for a routine eye exam or dry eye treatment. Dr. Ioussifova’s team creates a supportive environment by emphasizing individualized care from the outset, fostering trust and patient satisfaction. The Role of Meibography and Advanced Diagnostic Tools Early detection of MGD is critical, so Dr. Ioussifova incorporates meibography and meibomian gland expressibility tests into every dry eye consultation. With these tests, practitioners can view gland structures and assess their functionality. This data is invaluable for explaining evaporative dry eye to patients, showing them clear images of gland conditions, and helping them understand the importance of early intervention. MIEBO: The Only Rx Eye Drop for DED That Directly Targets Tear Evaporation MIEBO is a different kind of eye drop because it directly targets tear evaporation. MIEBO mimics key functions of natural meibum, addresses damage by promoting healing on the ocular surface, and may reduce friction. The exact mechanism of action for MIEBO in DED is not known. In clinical trials, MIEBO was shown to improve both signs and symptoms of dry eye disease in ~2 weeks—with continued improvement through ~8 weeks—when administered 4 times daily. The efficacy of MIEBO may appeal to patients who have experienced limited success with standard treatments. How MIEBO Fits Into Treatment Plans MIEBO is composed of only one ingredient—100% perfluorohexyloctane—making it vehicle-, preservative-, steroid-,

Distinct summary based on available episode metadata or transcript content.